Output

Meetings
Network members have satellite meetings at major psychedelic research conferences as well as a standalone meeting at the ECNP congress each year.

Recommended publications

Authors
Year
Title
Journal and link to the article
Erritzoe D, et al.
 2024 Effects of discontinuation of serotonergic antidepressants prior to psilocybin therapy versus escitalopram for major depression
 J Psychopharmacol
Holze et al.
2024 Ketanserin exhibits dose- and concentration-proportional serotonin 2A receptor occupancy in healthy individuals: Relevance for psychedelic research
 European Neuropsychopharmacology
McCulloch, D.E., et al
2024 Knowledge gaps in psychedelic medicalisation: Preclinical and neuroimaging mechanisms
 Neuroscience Applied
McCulloch, D.E., et al.
 2024  Knowledge gaps in psychedelic medicalisation: Clinical studies and regulatory aspects
 Neuroscience Applied
Breeksema, J.J., et al.
 2024 Patient perspectives and experiences with psilocybin treatment for treatment-resistant depression: a qualitative study.
Scientific Reports
Holze, F., et al.
2024 LSD-assisted therapy in people with anxiety: an open-label prospective 12-month follow-up.
British Journal of Psychiatry
Gründer, G., et al
 2024 Treatment with psychedelics is psychotherapy: beyond reductionism.
Lancet Psychiatry
Holze F., et al.
2024  Ketanserin exhibits dose- and concentration-proportional serotonin 2A receptor occupancy in healthy individuals: Relevance for psychedelic research European Neuropsychopharmacology
Erritzoe D, et al.
 2023 Exploring mechanisms of psychedelic action using neuroimaging
 Nature Mental Health
Moliner, R., et al.
2023 Psychedelics promote plasticity by directly binding to BDNF receptor TrkB
 Nature Neuroscience
Nikolič, M., et al.
2023 Psilocybin intoxication did not affect daytime or sleep-related declarative memory consolidation in a small sample exploratory analysis.
European Neuropsychopharmacology
Straumann, L., et al.
2023 Acute effects of MDMA and LSD co-administration in a double-blind placebo-controlled study in healthy participants
 Neuropsychopharmacology
Goodwin, G.M., et al.
2023 Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial. 
 eClinicalMedicine
Bulten-Ducuing et al. 2023 The therapeutic potential of psychedelics: the European regulatory perspective The Lancet
Grieco, S.F., et al.
2022 Psychedelics and Related Neural Plasticity-Promoting Compounds: Therapeutic Implications
 Journal of Neuroscience
Viktorin, V., et al.
2022 Psilocybin-mediated attenuation of gamma band auditory steady-state responses (ASSR) Is driven by the intensity of cognitive and emotional domains of psychedelic experience
 Journal of Personalized Medicine
Mertens, L.J., et al.
2022 Methodological challenges in psychedelic drug trials: Efficacy and safety of psilocybin in treatment-resistant major depression (EPIsoDE) – Rationale and study design.
Neuroscience Applied
Holze et al.
 2022 Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects.
Neuropsychopharmacology 
McCulloch et al.
2022 Psychedelic resting-state neuroimaging: a review and perspective on balancing replication and novel analyses.
Neuroscience & Biobehavioral Reviews
Carhart-Harris et al. 
 2021  Trial of psilocybin versus escitalopram for depression. 
 New England Journal of Medicine  
Vizeli et al.
 2021 Genetic influence of CYP2D6 on pharmacokinetics and acute subjective effects of LSD in a pooled analysis.
Scientific Reports
Stenbæk et al.
 2020 Brain serotonin 2A receptor binding predicts subjective temporal and mystical effects of psilocybin in healthy humans.
 Journal of Psychopharmacology
Madsen et al.
2019 Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels.   Neuropsychopharmacology
Preller et al.
 2018 Phenomenology, structure, and dynamic of psychedelic states.
Current Topics in Behavioral Neurosciences
Preller et al.
 2018 Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor.
eLife
Kuypers et al.
2016 Ayahuasca enhances creative divergent thinking while decreasing conventional convergent thinking.
Psychopharmacology

Pálen

íček et al.

2011 Electroencephalographic spectral and coherence analysis of ketamine in rats: correlation with behavioral effects and pharmacokinetics.
Neuropsychobiology

 

Collaborative projects

  • Data sharing and analysis
    - fMRI data sharing between groups
    - Cross-site analysis of plasma drug levels and metabolites
    - Behavioral data sharing
  • Drug sharing
    - Liechti Lab: Shares GMP drug products
    - Palenicek Lab: Shares non-GMP drugs and metabolites
  • Multi-site collaborations
    - Academic paper writing
    - Multi-site trial facilitation
    - PET work collaboration (Imperial Group with Copenhagen)
    - OCD and PET imaging collaboration (Imperial Group with other London groups)
    - Copenhagen-Helsinki collaboration on psychedelic-based BDNF ligands

  • Specialised services
    - Liechti Lab: Plasma drug quantification for other labs

Industrial collaborations

  • Clinical trials
    1) Imperial Group:
    - SmallPharma DMT depression phase 1 and 2a trials
    - USONA, COMPASS, and Filament compounds in Imperial studies

    2) Gründer group:
    - Beckley Psytech (5-Meo-DMT for treatment-resistant depression)
    - Cybin (Psilocybin for major depressive disorder)
    MindMed (LSD for generalized anxiety disorder)

Other collaborations

  • Gründer group:
    - MIND Foundation collaboration on psychedelic therapist training
    - EU-wide multicenter phase III trial preparation with psilocybin

  • Castren group
    - Kasvu Therapeutics

Interactions with regulators and policy-makers

  • EMA
    - Collaborated on a Lancet comment with members of the EMA: “The therapeutic potential of psychedelics: the European regulatory perspective”
    - Several members attended the EMA workshop on psychedelics on April 16-17, 2024

  • Swiss programme (Liechti lab)
    - Expert reports and quality control for Swiss limited use program
    - Guidelines for drug-drug interactions
    - Quality control coordination
    - Self-experience study for PAT training program participants

  • German regulatory engagement (Gründer group)
    Consultations with BfArM and G-BA on study design, regulation, and pricing
  • European policy collaboration
    Network collaboration with Psychedelics Europe and PAREA to inform European policy decisions

Meetings

  • October 2022
    ECNP Satellite Meeting
  • 6 July 2022
    Virtual start-up meeting (only for members of the Psychedelic research Network)

Research projects
TBD